Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

LAG-3 and TIGIT protein expressions in cutaneous melanoma and their relationship with PD-1 tumor-infiltrating lymphocytes.

Lee WJ, Lee YJ, Choi ME, Yun KA, Won CH, Lee MW, Choi JH, Chang SE.

J Am Acad Dermatol. 2019 Mar 14. pii: S0190-9622(19)30426-8. doi: 10.1016/j.jaad.2019.03.012. [Epub ahead of print]

PMID:
30880064
3.

TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.

Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, Kirkwood JM, Chen TH, Maurer M, Korman AJ, Zarour HM.

J Clin Invest. 2015 May;125(5):2046-58. doi: 10.1172/JCI80445. Epub 2015 Apr 13.

4.

Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.

Lee WJ, Lee YJ, Shin HJ, Won CH, Chang SE, Choi JH, Lee MW.

Melanoma Res. 2018 Oct;28(5):423-434. doi: 10.1097/CMR.0000000000000449.

PMID:
29634635
5.

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sékaly RP, Chomont N.

PLoS Pathog. 2016 Jul 14;12(7):e1005761. doi: 10.1371/journal.ppat.1005761. eCollection 2016 Jul.

6.

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA.

Mod Pathol. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110. Epub 2015 Sep 25.

7.

LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.

He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR.

J Thorac Oncol. 2017 May;12(5):814-823. doi: 10.1016/j.jtho.2017.01.019. Epub 2017 Jan 26.

8.

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.

Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S.

J Invest Dermatol. 2016 Jan;136(1):255-63. doi: 10.1038/JID.2015.404.

9.

LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.

Burugu S, Gao D, Leung S, Chia SK, Nielsen TO.

Ann Oncol. 2017 Dec 1;28(12):2977-2984. doi: 10.1093/annonc/mdx557.

PMID:
29045526
10.

Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma.

Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS, Xia JC.

Cancer Manag Res. 2018 Nov 28;10:6457-6468. doi: 10.2147/CMAR.S181949. eCollection 2018.

11.

Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.

Inozume T, Yaguchi T, Furuta J, Harada K, Kawakami Y, Shimada S.

J Invest Dermatol. 2015 Oct 12. doi: 10.1038/jid.2015.404. [Epub ahead of print]

PMID:
26458009
12.

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.

Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H.

J Hematol Oncol. 2017 Jun 19;10(1):124. doi: 10.1186/s13045-017-0486-z.

13.

Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.

Fleury M, Belkina AC, Proctor EA, Zammitti C, Simms RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H.

Arthritis Rheumatol. 2018 Apr;70(4):566-577. doi: 10.1002/art.40399. Epub 2018 Mar 7.

14.

Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma.

Lee WJ, Lee MH, Kim HT, Won CH, Lee MW, Choi JH, Chang SE.

Melanoma Res. 2018 Dec 19. doi: 10.1097/CMR.0000000000000549. [Epub ahead of print]

PMID:
30575644
15.

Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.

Chang H, Jung W, Kim A, Kim HK, Kim WB, Kim JH, Kim BH.

APMIS. 2017 Aug;125(8):690-698. doi: 10.1111/apm.12703. Epub 2017 May 11.

PMID:
28493410
16.

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH.

Clin Cancer Res. 2018 Feb 15;24(4):870-881. doi: 10.1158/1078-0432.CCR-17-2337. Epub 2017 Dec 7.

17.

Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.

Stålhammar G, Seregard S, Grossniklaus HE.

Cancer Med. 2019 Apr 16. doi: 10.1002/cam4.2167. [Epub ahead of print]

18.

PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.

Ren M, Dai B, Kong YY, Lv JJ, Cai X.

Histopathology. 2018 Sep;73(3):386-396. doi: 10.1111/his.13527. Epub 2018 Jun 8.

PMID:
29637587
19.

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.

Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park SM, Youn JI, Chowdhury T, Park CK, Brem H, Pardoll DM, Lim M.

Oncoimmunology. 2018 May 24;7(8):e1466769. doi: 10.1080/2162402X.2018.1466769. eCollection 2018.

20.

Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.

Ko YS, Pyo JS.

Int J Biol Markers. 2019 Mar 11:1724600818817320. doi: 10.1177/1724600818817320. [Epub ahead of print]

PMID:
30852949

Supplemental Content

Support Center